John T Cavan insider trades: Hepion Pharmaceuticals (HEPA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 18, 2021 | HEPA | ↑ Buy | 10,000 | $2.00 | $20K | Direct | Feb 18, 2021 (0d) |
| Nov 25, 2020 | HEPA | ↑ Buy | 4,500 | $1.62 | $7K | Direct | Nov 30, 2020 (5d) |
| Jun 20, 2017 | CTRV | ↑ Buy | 20,000 | $0.65 | $13K | Direct | Jun 22, 2017 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other HEPA insiders
Open-market trades in the last 12 months
About John T Cavan's insider trades
John T Cavan is Chief Financial Officer at Hepion Pharmaceuticals (HEPA). Since Jun 20, 2017, John has reported 3 open-market purchases worth $40K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HEPA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.